Biosyent Inc V.RX

Alternate Symbol(s): BIOYF

Healthcare

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.

TSXV:RX - Post by User

Biosyent Inc

Bullboard Posts

Comment by rtftech16on Feb 20, 2019 4:54pm

34 Views

Post# 29390536

RE:RE:RE:RE:RE:Honest question

For clarity, when I look at a company I do a discounted future cash flow calculation and look at tangible book value per share. I get around $4.50 for the next 5 years with my discounted future cash flow calculation.

can someone provide me with their calculation because I’m having trouble understanding why this is worth more than what I have calculated for it’s discounted future cash flow per share for the next 5 years.

For other companies I look at I consider this to be OK if they would usually be trading at about price to tangible book which would justify it, but this isn’t trading at all close to price to tangible book in my opinion

Thanks

Bullboard Posts

What will the U.S. election results mean for Canada?